{"pmid":32452539,"title":"COVID-19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019-nCoV disease.","text":["COVID-19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019-nCoV disease.","Months after the outbreak of a new flu-like disease in China, the entire world is now in a state of caution. The subsequent less-anticipated propagation of the novel coronavirus disease, formally known as COVID-19, not only made it to headlines by an overwhelmingly high transmission rate and fatality reports, but also raised an alarm for the medical community all around the globe. Since the causative agent, SARS-CoV-2, is a recently discovered species, there is no specific medicine for downright treatment of the infection. This has led to an unprecedented societal fear of the newly born disease, adding a psychological aspect to the physical manifestation of the virus. Herein, the COVID-19 structure, epidemiology, pathogenesis, etiology, diagnosis, and therapy have been reviewed.","J Cell Physiol","Sheervalilou, Roghayeh","Shirvaliloo, Milad","Dadashzadeh, Nahid","Shirvalilou, Sakine","Shahraki, Omolbanin","Pilehvar-Soltanahmadi, Younes","Ghaznavi, Habib","Khoei, Samideh","Nazarlou, Ziba","32452539"],"abstract":["Months after the outbreak of a new flu-like disease in China, the entire world is now in a state of caution. The subsequent less-anticipated propagation of the novel coronavirus disease, formally known as COVID-19, not only made it to headlines by an overwhelmingly high transmission rate and fatality reports, but also raised an alarm for the medical community all around the globe. Since the causative agent, SARS-CoV-2, is a recently discovered species, there is no specific medicine for downright treatment of the infection. This has led to an unprecedented societal fear of the newly born disease, adding a psychological aspect to the physical manifestation of the virus. Herein, the COVID-19 structure, epidemiology, pathogenesis, etiology, diagnosis, and therapy have been reviewed."],"journal":"J Cell Physiol","authors":["Sheervalilou, Roghayeh","Shirvaliloo, Milad","Dadashzadeh, Nahid","Shirvalilou, Sakine","Shahraki, Omolbanin","Pilehvar-Soltanahmadi, Younes","Ghaznavi, Habib","Khoei, Samideh","Nazarlou, Ziba"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32452539","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jcp.29735","keywords":["2019-ncov or covid-19 or sars-cov-2","diagnosis","epidemiology","etiology","pathogenesis","therapy"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Transmission","Diagnosis","Mechanism"],"weight":1,"_version_":1667983494477774848,"score":9.490897,"similar":[{"pmid":32482591,"title":"Swine enteric alphacoronavirus (swine acute diarrhea syndrome coronavirus): An update three years after its discovery.","text":["Swine enteric alphacoronavirus (swine acute diarrhea syndrome coronavirus): An update three years after its discovery.","Discovered in 2017, swine enteric alphacoronavirus (SeACoV), also known as swine acute diarrhea syndrome coronavirus (SADS-CoV) or porcine enteric alphacoronavirus (PEAV), is the fifth porcine CoV identified in diarrheal piglets. The presumed name \"SADS-CoV\" may not be appropriate since current studies have not provided strong evidence for high pathogenicity of the virus. SeACoV was the most recently recognized CoV of potential bat origin prior to the novel human severe acute respiratory syndrome CoV 2 (SARS-CoV-2), associated with the pandemic CoV disease 2019 (COVID-19). Although SeACoV is recognized as a regional epizootic virus currently, it possesses the most extensive cell species tropism in vitro among known CoVs. This review summarizes the emergence of SeACoV and updates the research progress made from 2017 to early 2020, mainly focusing on the etiology, epidemiology, evolutionary perspective, potential for interspecies transmission, pathogenesis and diagnosis.","Virus Res","Yang, Yong-Le","Yu, Jia-Qi","Huang, Yao-Wei","32482591"],"abstract":["Discovered in 2017, swine enteric alphacoronavirus (SeACoV), also known as swine acute diarrhea syndrome coronavirus (SADS-CoV) or porcine enteric alphacoronavirus (PEAV), is the fifth porcine CoV identified in diarrheal piglets. The presumed name \"SADS-CoV\" may not be appropriate since current studies have not provided strong evidence for high pathogenicity of the virus. SeACoV was the most recently recognized CoV of potential bat origin prior to the novel human severe acute respiratory syndrome CoV 2 (SARS-CoV-2), associated with the pandemic CoV disease 2019 (COVID-19). Although SeACoV is recognized as a regional epizootic virus currently, it possesses the most extensive cell species tropism in vitro among known CoVs. This review summarizes the emergence of SeACoV and updates the research progress made from 2017 to early 2020, mainly focusing on the etiology, epidemiology, evolutionary perspective, potential for interspecies transmission, pathogenesis and diagnosis."],"journal":"Virus Res","authors":["Yang, Yong-Le","Yu, Jia-Qi","Huang, Yao-Wei"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32482591","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.virusres.2020.198024","keywords":["diagnosis","etiology","pathogenicity","swine acute diarrhea syndrome coronavirus (sads-cov)","swine enteric alphacoronavirus (seacov)","transmission"],"topics":["Mechanism","Diagnosis","Transmission"],"weight":1,"_version_":1668532114856869889,"score":194.81439},{"pmid":32425279,"pmcid":"PMC7229464","title":"Swine enteric alphacoronavirus (swine acute diarrhea syndrome coronavirus): an update three years after its discovery.","text":["Swine enteric alphacoronavirus (swine acute diarrhea syndrome coronavirus): an update three years after its discovery.","Discovered in 2017, swine enteric alphacoronavirus (SeACoV), also known as swine acute diarrhea syndrome coronavirus (SADS-CoV) or porcine enteric alphacoronavirus (PEAV), is the fifth porcine CoV identified in diarrheal piglets. The presumed name \"SADS-CoV\" may not be appropriate since current studies have not provided strong evidence for high pathogenicity of the virus. SeACoV was the most recently recognized CoV of potential bat origin prior to the novel human severe acute respiratory syndrome CoV 2 (SARS-CoV-2), associated with the pandemic CoV disease 2019 (COVID-19). Although SeACoV is recognized as a regional epizootic virus currently, it possesses the most extensive cell species tropism in vitro among known CoVs. This review summarizes the emergence of SeACoV and updates the research progress made from 2017 to early 2020, mainly focusing on the etiology, epidemiology, evolutionary perspective, potential for interspecies transmission, pathogenesis and diagnosis.","Virus Res","Yang, Yong-Le","Yu, Jia-Qi","Huang, Yao-Wei","32425279"],"abstract":["Discovered in 2017, swine enteric alphacoronavirus (SeACoV), also known as swine acute diarrhea syndrome coronavirus (SADS-CoV) or porcine enteric alphacoronavirus (PEAV), is the fifth porcine CoV identified in diarrheal piglets. The presumed name \"SADS-CoV\" may not be appropriate since current studies have not provided strong evidence for high pathogenicity of the virus. SeACoV was the most recently recognized CoV of potential bat origin prior to the novel human severe acute respiratory syndrome CoV 2 (SARS-CoV-2), associated with the pandemic CoV disease 2019 (COVID-19). Although SeACoV is recognized as a regional epizootic virus currently, it possesses the most extensive cell species tropism in vitro among known CoVs. This review summarizes the emergence of SeACoV and updates the research progress made from 2017 to early 2020, mainly focusing on the etiology, epidemiology, evolutionary perspective, potential for interspecies transmission, pathogenesis and diagnosis."],"journal":"Virus Res","authors":["Yang, Yong-Le","Yu, Jia-Qi","Huang, Yao-Wei"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425279","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.virusres.2020.198024","keywords":["diagnosis","etiology","pathogenicity","swine acute diarrhea syndrome coronavirus (sads-cov)","swine enteric alphacoronavirus (seacov)","transmission"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1667252837863653377,"score":178.62254},{"pmid":32113704,"pmcid":"PMC7127067","title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.","text":["The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.","Coronavirus disease (COVID-19) is caused by SARS-COV2 and represents the causative agent of a potentially fatal disease that is of great global public health concern. Based on the large number of infected people that were exposed to the wet animal market in Wuhan City, China, it is suggested that this is likely the zoonotic origin of COVID-19. Person-to-person transmission of COVID-19 infection led to the isolation of patients that were subsequently administered a variety of treatments. Extensive measures to reduce person-to-person transmission of COVID-19 have been implemented to control the current outbreak. Special attention and efforts to protect or reduce transmission should be applied in susceptible populations including children, health care providers, and elderly people. In this review, we highlights the symptoms, epidemiology, transmission, pathogenesis, phylogenetic analysis and future directions to control the spread of this fatal disease.","J Autoimmun","Rothan, Hussin A","Byrareddy, Siddappa N","32113704"],"abstract":["Coronavirus disease (COVID-19) is caused by SARS-COV2 and represents the causative agent of a potentially fatal disease that is of great global public health concern. Based on the large number of infected people that were exposed to the wet animal market in Wuhan City, China, it is suggested that this is likely the zoonotic origin of COVID-19. Person-to-person transmission of COVID-19 infection led to the isolation of patients that were subsequently administered a variety of treatments. Extensive measures to reduce person-to-person transmission of COVID-19 have been implemented to control the current outbreak. Special attention and efforts to protect or reduce transmission should be applied in susceptible populations including children, health care providers, and elderly people. In this review, we highlights the symptoms, epidemiology, transmission, pathogenesis, phylogenetic analysis and future directions to control the spread of this fatal disease."],"journal":"J Autoimmun","authors":["Rothan, Hussin A","Byrareddy, Siddappa N"],"date":"2020-03-02T11:00:00Z","year":2020,"_id":"32113704","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.jaut.2020.102433","keywords":["covid-19","coronavirus","pathogenesis","pneumonia","wuhan city"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Transmission","Mechanism","Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1666138490759282688,"score":154.52316},{"pmid":32169119,"pmcid":"PMC7068984","title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.","text":["The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.","An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to beta-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.","Mil Med Res","Guo, Yan-Rong","Cao, Qing-Dong","Hong, Zhong-Si","Tan, Yuan-Yang","Chen, Shou-Deng","Jin, Hong-Jun","Tan, Kai-Sen","Wang, De-Yun","Yan, Yan","32169119"],"abstract":["An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to beta-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus."],"journal":"Mil Med Res","authors":["Guo, Yan-Rong","Cao, Qing-Dong","Hong, Zhong-Si","Tan, Yuan-Yang","Chen, Shou-Deng","Jin, Hong-Jun","Tan, Kai-Sen","Wang, De-Yun","Yan, Yan"],"date":"2020-03-15T11:00:00Z","year":2020,"_id":"32169119","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.1186/s40779-020-00240-0","keywords":["clinical characteristics","coronavirus disease 2019 (covid-19)","origin","sars-cov-2","therapy","transmission"],"locations":["China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment","Transmission"],"weight":1,"_version_":1666138490634502144,"score":148.41953},{"pmid":32434058,"title":"A chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatment.","text":["A chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatment.","In order to benefit the public, community workers and scientific community, we hereby present a chronicle of SARS-CoV-2 that leads to the unseen precedent of social distancing and lockdown owing to coronavirus disease (COVID-19). Information on this life-threatening pandemic of COVID-19 is sparse and discrete; and the urgency is such that the dissemination of information is increasing with numerous daily publications on the topic. Therefore, we developed a comprehensive review on various aspects of SARS-CoV-2 and COVID-19. We scientifically compiled published research, news, and reports from various sources to comprehend and summarize the information and findings on Coronaviruses. The review explicitly covers the aspects like genome and pedigree of SARS-CoV-2; epidemiology, prognosis, pathogenesis, symptoms and diagnosis of COVID-19 in order to catalog the right information on transmission route, and influence of environmental factors on virus transmissions, for the robust understanding of right strategical steps for proper COVID-19 management. We have explicitly highlighted several useful information and facts like: i) No established relationship between progression of SARS-CoV-2 with temperature, humidity and/or both, ii) The underlying mechanism of SARS-CoV-2 is not fully understood, iii) Respiratory droplet size determines drop and airborne-based transmission, iv) Prognosis of COVID-19 can be done by its effects on various body organs, v) Infection can be stopped by restricting the binding of S protein and AE2, vi) Hydroxychloroquine is believed to be better than chloroquine for COVID-19, vii) Ivermectin with Vero-hSLAM cells is able to reduce infection by ~5000 time within 2 days, and viii) Nafamostat mesylate can inhibit SARS-CoV-2 S protein-initiated membrane fusion. We have also suggested future research perspectives, challenges and scope.","Sci Total Environ","Kumar, Manish","Taki, Kaling","Gahlot, Rohit","Sharma, Ayushi","Dhangar, Kiran","32434058"],"abstract":["In order to benefit the public, community workers and scientific community, we hereby present a chronicle of SARS-CoV-2 that leads to the unseen precedent of social distancing and lockdown owing to coronavirus disease (COVID-19). Information on this life-threatening pandemic of COVID-19 is sparse and discrete; and the urgency is such that the dissemination of information is increasing with numerous daily publications on the topic. Therefore, we developed a comprehensive review on various aspects of SARS-CoV-2 and COVID-19. We scientifically compiled published research, news, and reports from various sources to comprehend and summarize the information and findings on Coronaviruses. The review explicitly covers the aspects like genome and pedigree of SARS-CoV-2; epidemiology, prognosis, pathogenesis, symptoms and diagnosis of COVID-19 in order to catalog the right information on transmission route, and influence of environmental factors on virus transmissions, for the robust understanding of right strategical steps for proper COVID-19 management. We have explicitly highlighted several useful information and facts like: i) No established relationship between progression of SARS-CoV-2 with temperature, humidity and/or both, ii) The underlying mechanism of SARS-CoV-2 is not fully understood, iii) Respiratory droplet size determines drop and airborne-based transmission, iv) Prognosis of COVID-19 can be done by its effects on various body organs, v) Infection can be stopped by restricting the binding of S protein and AE2, vi) Hydroxychloroquine is believed to be better than chloroquine for COVID-19, vii) Ivermectin with Vero-hSLAM cells is able to reduce infection by ~5000 time within 2 days, and viii) Nafamostat mesylate can inhibit SARS-CoV-2 S protein-initiated membrane fusion. We have also suggested future research perspectives, challenges and scope."],"journal":"Sci Total Environ","authors":["Kumar, Manish","Taki, Kaling","Gahlot, Rohit","Sharma, Ayushi","Dhangar, Kiran"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32434058","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.scitotenv.2020.139278","keywords":["covid-19","mers-cov","pathogenesis","sars-cov","sars-cov-2","transmission"],"locations":["Nafamostat"],"topics":["Treatment","Transmission","Diagnosis","Mechanism"],"weight":1,"_version_":1667342288147185665,"score":147.73141}]}